PubRank

Sandra M Swain

Author PubWeight™ 166.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 33.60
2 Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2011 12.45
3 Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009 6.28
4 Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005 4.77
5 Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012 4.57
6 Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012 4.10
7 Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003 4.06
8 Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006 3.62
9 Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011 3.54
10 Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006 3.53
11 Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006 2.93
12 Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004 2.72
13 Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012 2.65
14 Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013 2.59
15 Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 2012 2.34
16 Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst 2013 2.28
17 Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004 1.85
18 Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008 1.83
19 Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002 1.82
20 Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 2008 1.81
21 Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004 1.72
22 Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther 2007 1.68
23 Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011 1.56
24 The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009 1.52
25 Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008 1.50
26 Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007 1.50
27 Locally advanced and inflammatory breast cancer. J Clin Oncol 2008 1.44
28 Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008 1.42
29 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005 1.41
30 Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002 1.40
31 Amenorrhea from breast cancer therapy--not a matter of dose. N Engl J Med 2010 1.40
32 Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. Radiology 2007 1.24
33 ASCO's approach to a learning health care system in oncology. J Oncol Pract 2013 1.22
34 Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 2010 1.08
35 CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010 1.08
36 Therapeutic strategies for triple-negative breast cancer. Cancer J 2008 1.05
37 Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J Clin Oncol 2011 1.05
38 Clinical aspects of inflammatory breast cancer. Breast Dis 2006 1.03
39 Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 2013 1.02
40 Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Res Treat 2011 1.01
41 Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005 1.00
42 Aromatase inhibitors--a triumph of translational oncology. N Engl J Med 2005 1.00
43 Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 2007 0.98
44 Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol 2003 0.98
45 Drug discount program. JAMA 2013 0.97
46 Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol 2010 0.96
47 Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 2004 0.95
48 Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res 2005 0.94
49 The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 2008 0.93
50 A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 2004 0.92
51 Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci 2003 0.92
52 A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology 2007 0.88
53 A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trials. Oncologist 2012 0.87
54 Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol 2006 0.87
55 A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat 2006 0.86
56 Concepts and clinical trials of dose-dense chemotherapy for breast cancer . Clin Breast Cancer 2005 0.86
57 Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2006 0.86
58 A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer 2006 0.85
59 A step in the right direction. J Clin Oncol 2006 0.85
60 Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006 0.84
61 Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer. Clin Breast Cancer 2012 0.83
62 The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010 0.83
63 A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Invest New Drugs 2007 0.83
64 Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer 2011 0.83
65 Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. Cancer Med 2013 0.82
66 Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer 2014 0.82
67 Primary systemic chemotherapy for inflammatory breast cancer. Cancer 2010 0.82
68 CA 125 elevation in breast cancer: a case report and review of the literature. Breast J 2004 0.82
69 NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med 2013 0.81
70 Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs 2013 0.81
71 Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat 2013 0.81
72 Cardiac dysfunction after cancer treatment. Tex Heart Inst J 2011 0.80
73 Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opin Investig Drugs 2008 0.80
74 The heart of the matter. J Clin Oncol 2007 0.80
75 Contralateral breast cancer: where does it all begin? J Clin Oncol 2005 0.80
76 Pertuzumab for the treatment of breast cancer. Cancer Invest 2014 0.79
77 Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin Oncol 2002 0.79
78 p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. Int J Oncol 2011 0.79
79 Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin Emerg Drugs 2006 0.78
80 Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. Expert Opin Biol Ther 2013 0.78
81 Treatment and cost implications of pertuzumab. Am J Manag Care 2012 0.77
82 Treatment of HER2-positive metastatic breast cancer. N Engl J Med 2015 0.77
83 A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. Clin Breast Cancer 2005 0.76
84 Pazopanib for the treatment of breast cancer. Expert Opin Investig Drugs 2012 0.76
85 Meta-analysis: should it be more than the sum of its parts? J Natl Cancer Inst 2010 0.75
86 Pertuzumab: increasing the options. Oncology (Williston Park) 2014 0.75
87 Oophorectomy in carriers of BRCA mutations. N Engl J Med 2002 0.75
88 First, do no harm. Onkologie 2008 0.75
89 Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer. Clin Breast Cancer 2004 0.75
90 Avastin withdrawal symptoms. Expert Opin Pharmacother 2012 0.75